Robinson, Mitchell B.
Renna, Marco
Ozana, Nisan
Martin, Alyssa N.
Otic, Nikola
Carp, Stefan A.
Franceschini, Maria Angela
Funding for this research was provided by:
National Institute of Biomedical Imaging and Bioengineering (T32EB001680, R01EB033202, U01EB028660)
Article History
Received: 26 February 2023
Accepted: 29 May 2023
First Online: 31 May 2023
Competing interests
: M.A.F had a financial interest in 149 Medical, Inc., a company developing DCS technology for assessing and monitoring cerebral blood flow in newborn infants. M.A.F.’s interests are managed by Mass General Hospital, and Mass General Brigham in accordance with their conflict-of-interest policies. M.B.R, M.R., N.N.O., A.N.M, N.O., and S.A.C. have nothing to report.